{"id":77571,"date":"2026-08-31T21:02:14","date_gmt":"2026-08-31T13:02:14","guid":{"rendered":"https:\/\/flcube.com\/?p=77571"},"modified":"2026-08-31T21:02:15","modified_gmt":"2026-08-31T13:02:15","slug":"ascletis-doses-first-patient-in-global-phase-3-aurora-trial-of-oral-glp-1-candidate-asc30","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77571","title":{"rendered":"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Ascletis Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1672:HKG\">HKG: 1672<\/a>) announced that the first participant has been dosed in the global Phase 3 <strong>AURORA<\/strong> clinical program of <strong>ASC30<\/strong>, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.<\/p>\n\n\n\n<h2 id=\"h-clinical-milestone\" class=\"wp-block-heading\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Company<\/td><td><strong>Ascletis Pharma Inc.<\/strong> (HKG: 1672)<\/td><\/tr><tr><td>Asset<\/td><td><strong>ASC30<\/strong>, once\u2011daily oral small molecule GLP\u20111 receptor agonist<\/td><\/tr><tr><td>Program<\/td><td>Phase 3 AURORA global clinical program<\/td><\/tr><tr><td>Indication<\/td><td>Chronic weight management (obesity and overweight)<\/td><\/tr><tr><td>Date<\/td><td>First participant dosed on 30 Aug 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Enrollment of ~4,600 participants across the U.S., Europe, and Canada<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile\" class=\"wp-block-heading\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> ASC30 \u2014 developed in\u2011house by Ascletis<\/li>\n\n\n\n<li><strong>Modality:<\/strong> Small molecule GLP\u20111 receptor agonist<\/li>\n\n\n\n<li><strong>Dosing:<\/strong> Once\u2011daily oral administration \u2014 a key convenience advantage over injectable GLP\u20111 therapies<\/li>\n\n\n\n<li><strong>Doses Under Evaluation:<\/strong> Three maintenance doses \u2014 20 mg, 40 mg, and 60 mg<\/li>\n\n\n\n<li><strong>Origin:<\/strong> Proprietary asset, wholly developed by Ascletis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-aurora-phase-3-program\" class=\"wp-block-heading\">Clinical Evidence \u2013 AURORA Phase 3 Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>Population<\/th><th>NCT<\/th><th>Duration<\/th><\/tr><\/thead><tbody><tr><td><strong>AURORA\u20111<\/strong><\/td><td>Obesity or overweight without type 2 diabetes<\/td><td>NCT07743463<\/td><td>72 weeks<\/td><\/tr><tr><td><strong>AURORA\u20112<\/strong><\/td><td>Obesity or overweight with type 2 diabetes<\/td><td>NCT07743450<\/td><td>72 weeks<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The AURORA program plans to enroll approximately <strong>4,600 participants<\/strong> across clinical sites in the <strong>U.S., Europe, and Canada<\/strong>, evaluating the efficacy and safety of ASC30&#8217;s three maintenance doses over 72 weeks. The dual\u2011study design covers both major obesity populations \u2014 with and without type 2 diabetes \u2014 mirroring the registration strategy employed by leading competitors in the field.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral GLP\u20111 Race:<\/strong> First\u2011patient\u2011dosed status places Ascletis among the cohort of companies pursuing the oral GLP\u20111 opportunity, widely viewed as the next growth phase of the obesity market<\/li>\n\n\n\n<li><strong>Convenience Edge:<\/strong> A once\u2011daily small molecule pill could lower barriers to treatment initiation and adherence relative to injectables<\/li>\n\n\n\n<li><strong>Scale of Evidence:<\/strong> ~4,600 participants and 72 weeks of treatment position AURORA as a registrational\u2011grade data package for global markets<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Successful Phase 3 execution would establish Ascletis as a serious contender in chronic weight management and materially enhance partnering potential<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding the enrollment, clinical outcomes, and regulatory prospects of the ASC30 AURORA Phase 3 program. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026083000012_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026083000012_c.\"><\/object><a id=\"wp-block-file--media-c110f17d-2840-4f8a-b60b-eaac082b2c28\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026083000012_c.pdf\">2026083000012_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026083000012_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c110f17d-2840-4f8a-b60b-eaac082b2c28\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[189,980],"class_list":["post-77571","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-ascletis-pharma","tag-hkg-1672"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the global Phase 3 AURORA clinical program of ASC30, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77571\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the global Phase 3 AURORA clinical program of ASC30, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77571\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T13:02:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T13:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77571#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77571\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30\",\"datePublished\":\"2026-08-31T13:02:14+00:00\",\"dateModified\":\"2026-08-31T13:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77571\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascletis Pharma\",\"HKG: 1672\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77571#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77571\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77571\",\"name\":\"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-31T13:02:14+00:00\",\"dateModified\":\"2026-08-31T13:02:15+00:00\",\"description\":\"Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the global Phase 3 AURORA clinical program of ASC30, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77571#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77571\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77571#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30 - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the global Phase 3 AURORA clinical program of ASC30, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77571","og_locale":"en_US","og_type":"article","og_title":"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30","og_description":"Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the global Phase 3 AURORA clinical program of ASC30, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.","og_url":"https:\/\/flcube.com\/?p=77571","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T13:02:14+00:00","article_modified_time":"2026-08-31T13:02:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77571#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77571"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30","datePublished":"2026-08-31T13:02:14+00:00","dateModified":"2026-08-31T13:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77571"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascletis Pharma","HKG: 1672"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77571#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77571","url":"https:\/\/flcube.com\/?p=77571","name":"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-31T13:02:14+00:00","dateModified":"2026-08-31T13:02:15+00:00","description":"Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the global Phase 3 AURORA clinical program of ASC30, its proprietary once\u2011daily oral small molecule GLP\u20111 receptor agonist, for chronic weight management. The milestone advances Ascletis into one of the largest late\u2011stage trials of an oral GLP\u20111 in obesity, a segment currently dominated by injectable therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77571#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77571"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77571#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP\u20111 Candidate ASC30"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77571"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77571\/revisions"}],"predecessor-version":[{"id":77573,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77571\/revisions\/77573"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77571"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77571"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}